Press Coverage

valuation of up to 33.5 times, according Tina Banerjee, a healthcare analyst who publishes on the SMARTKARMA platform.  “The company has established client relationship with each of the 20 largest biopharmaceutical companies in the world by

other than the offerer. An attractive offer should facilitate the offer being declared unconditional, said Arun George, an analyst who publishes on SMARTKARMA. “The offer price represents an all-time high as it is 1.2% higher than the all-time share price of HK$33.60” in January 2022,

advanced economies, mainly due to inadequate dividend distributions, Sanghyun Park, founder of Clepsydra Capital, wrote in a note on SMARTKARMA.  “The May 2nd guideline release date is crucial for Value-up momentum trading,” he wrote. SECTORS IN FOCUS

really unique to gather much interest,” according to Aequitas Research analyst Sumeet Singh, who publishes on platform SMARTKARMA. Read More: Business Travel Perks Dwindle Amid Deal Slump: Hong Kong Edition

countries have effectively implemented such a system on a global scale,” said Sanghyun Park, founder of Clepsydra Capital, who publishes on SMARTKARMA. “Consequently, the prospect of Korea pioneering such an endeavor carries heightened risks.”